# Semaglutide Reduce

Meilleurs épisodes de podcast
Actualisé:

Can oral semaglutide reduce heart failure events in patients with heart failure with preserved ejection fraction?

Oral semaglutide reduced heart failure hospitalizations and cardiovascular death in type 2 diabetes patients with existing heart failure, particularly those with preserved ejection fraction, but showed no benefit in those without baseline heart failure. Modern total hip replacements demonstrate exc…

Semaglutide reduces cardiovascular event risk in people without diabetes

Does semaglutide reduce cardiovascular risk in patients without diabetes? Find out about this and more in today’s PV Roundup podcast.

Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients

Host: Carol Wysham Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. No…

Primary Care Article Recap - June 2024

Catch up on the most clinically-relevant articles from the April 2024 CFP Journal. This month we discuss How Does Prescribing a High-Dose Statin Compare to a "Treat-to Target" Strategy in Patients With Coronary Artery Disease, Can Semaglutide Reduce Cardiovascular Events in Obese Adults Without Dia…

Dad Joke Medicine - May 2024

Catch up on the most clinically-relevant articles from the April 2024 CFP Journal. This month we discuss How Does Prescribing a High-Dose Statin Compare to a "Treat-to Target" Strategy in Patients With Coronary Artery Disease, Can Semaglutide Reduce Cardiovascular Events in Obese Adults Without Dia…

Dad Joke Medicine - April 2024

Catch up on the most clinically-relevant articles from the April 2024 CFP Journal. This month we discuss How Does Prescribing a High-Dose Statin Compare to a "Treat-to Target" Strategy in Patients With Coronary Artery Disease, Can Semaglutide Reduce Cardiovascular Events in Obese Adults Without Dia…

Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients

Host: Carol Wysham, MD Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes…

GLP-1 Drugs Cut Heart Attack Risk — And It Has Nothing to Do With Weight

SELECT trial explained: does semaglutide reduce cardiovascular risk because of weight loss, or is something else going on? In this video, I break down the SELECT trial and the follow-up analysis examining whether the cardiovascular benefit of semaglutide was directly mediated by weight loss. The an…